These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 29692263)

  • 1. Liposomes Co- encapsulating Anticancer Drugs in Synergistic Ratios as an Approach to Promote Increased Efficacy and Greater Safety.
    Franco MS; Oliveira MC
    Anticancer Agents Med Chem; 2019; 19(1):17-28. PubMed ID: 29692263
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ratiometric dosing of anticancer drug combinations: controlling drug ratios after systemic administration regulates therapeutic activity in tumor-bearing mice.
    Mayer LD; Harasym TO; Tardi PG; Harasym NL; Shew CR; Johnstone SA; Ramsay EC; Bally MB; Janoff AS
    Mol Cancer Ther; 2006 Jul; 5(7):1854-63. PubMed ID: 16891472
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased preclinical efficacy of irinotecan and floxuridine coencapsulated inside liposomes is associated with tumor delivery of synergistic drug ratios.
    Harasym TO; Tardi PG; Harasym NL; Harvie P; Johnstone SA; Mayer LD
    Oncol Res; 2007; 16(8):361-74. PubMed ID: 17913044
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effective co-encapsulation of doxorubicin and irinotecan for synergistic therapy using liposomes prepared with triethylammonium sucrose octasulfate as drug trapping agent.
    Liu J; Chi D; Pan S; Zhao L; Wang X; Wang D; Wang Y
    Int J Pharm; 2019 Feb; 557():264-272. PubMed ID: 30599233
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug ratio-dependent antagonism: a new category of multidrug resistance and strategies for its circumvention.
    Harasym TO; Liboiron BD; Mayer LD
    Methods Mol Biol; 2010; 596():291-323. PubMed ID: 19949929
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improving combination cancer therapy: the CombiPlex
    Tolcher AW; Mayer LD
    Future Oncol; 2018 Jun; 14(13):1317-1332. PubMed ID: 29363994
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vivo maintenance of synergistic cytarabine:daunorubicin ratios greatly enhances therapeutic efficacy.
    Tardi P; Johnstone S; Harasym N; Xie S; Harasym T; Zisman N; Harvie P; Bermudes D; Mayer L
    Leuk Res; 2009 Jan; 33(1):129-39. PubMed ID: 18676016
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimization of vincristine-topotecan combination--paving the way for improved chemotherapy regimens by nanoliposomes.
    Zucker D; Barenholz Y
    J Control Release; 2010 Sep; 146(3):326-33. PubMed ID: 20685223
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CPX-351: a nanoscale liposomal co-formulation of daunorubicin and cytarabine with unique biodistribution and tumor cell uptake properties.
    Mayer LD; Tardi P; Louie AC
    Int J Nanomedicine; 2019; 14():3819-3830. PubMed ID: 31213803
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Schedule- and dose-dependency of CPX-351, a synergistic fixed ratio cytarabine:daunorubicin formulation, in consolidation treatment against human leukemia xenografts.
    Lim WS; Tardi PG; Xie X; Fan M; Huang R; Ciofani T; Harasym TO; Mayer LD
    Leuk Lymphoma; 2010 Aug; 51(8):1536-42. PubMed ID: 20528246
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of nanoscale delivery systems to maintain synergistic drug ratios in vivo.
    Dicko A; Mayer LD; Tardi PG
    Expert Opin Drug Deliv; 2010 Dec; 7(12):1329-41. PubMed ID: 21118030
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimizing combination chemotherapy by controlling drug ratios.
    Mayer LD; Janoff AS
    Mol Interv; 2007 Aug; 7(4):216-23. PubMed ID: 17827442
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The formulation of lipid-based nanotechnologies for the delivery of fixed dose anticancer drug combinations.
    Ramsay EC; Dos Santos N; Dragowska WH; Laskin JJ; Bally MB
    Curr Drug Deliv; 2005 Oct; 2(4):341-51. PubMed ID: 16305437
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ratiometric co-encapsulation and co-delivery of doxorubicin and paclitaxel by tumor-targeted lipodisks for combination therapy of breast cancer.
    Feng C; Zhang H; Chen J; Wang S; Xin Y; Qu Y; Zhang Q; Ji W; Yamashita F; Rui M; Xu X
    Int J Pharm; 2019 Apr; 560():191-204. PubMed ID: 30769131
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development and evaluation of oxaliplatin and irinotecan co-loaded liposomes for enhanced colorectal cancer therapy.
    Zhang B; Wang T; Yang S; Xiao Y; Song Y; Zhang N; Garg S
    J Control Release; 2016 Sep; 238():10-21. PubMed ID: 27432750
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro and in vivo characterization of a combination chemotherapy formulation consisting of vinorelbine and phosphatidylserine.
    Webb MS; Johnstone S; Morris TJ; Kennedy A; Gallagher R; Harasym N; Harasym T; Shew CR; Tardi P; Dragowska WH; Mayer LD; Bally MB
    Eur J Pharm Biopharm; 2007 Mar; 65(3):289-99. PubMed ID: 17123800
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antiproliferative Activity and VEGF Expression Reduction in MCF7 and PC-3 Cancer Cells by Paclitaxel and Imatinib Co-encapsulation in Folate-Targeted Liposomes.
    Peres-Filho MJ; Dos Santos AP; Nascimento TL; de Ávila RI; Ferreira FS; Valadares MC; Lima EM
    AAPS PharmSciTech; 2018 Jan; 19(1):201-212. PubMed ID: 28681330
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Liposomal encapsulation of a synergistic molar ratio of cytarabine and daunorubicin enhances selective toxicity for acute myeloid leukemia progenitors as compared to analogous normal hematopoietic cells.
    Kim HP; Gerhard B; Harasym TO; Mayer LD; Hogge DE
    Exp Hematol; 2011 Jul; 39(7):741-50. PubMed ID: 21530609
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Co-loaded paclitaxel/rapamycin liposomes: Development, characterization and in vitro and in vivo evaluation for breast cancer therapy.
    Eloy JO; Petrilli R; Topan JF; Antonio HMR; Barcellos JPA; Chesca DL; Serafini LN; Tiezzi DG; Lee RJ; Marchetti JM
    Colloids Surf B Biointerfaces; 2016 May; 141():74-82. PubMed ID: 26836480
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination Cancer Therapy Using Multifunctional Liposomes.
    Jain A; Tiwari A; Verma A; Saraf S; Jain SK
    Crit Rev Ther Drug Carrier Syst; 2020; 37(2):105-134. PubMed ID: 32865902
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.